Phase 2 colon cancer data from Agenus show 72 percent pathologic complete response

Phase 2 colon cancer data from Agenus show 72 percent pathologic complete response
Agenus posts colon cancer trial data

Agenus announced new phase 2 clinical data at ESMO26 showing that 83 percent of patients with locally advanced dMMR colon cancer who received BOT and BAL before surgery achieved a major pathologic response.

Additionally, 72 percent of patients reached a pathologic complete response following the treatment. The results highlight progress in treatment options for this specific subtype of colon cancer.

Agenus recently secured Armenia’s first marketing authorization for its BOT plus BAL therapy in adults with previously treated MSS mCRC, according to a company announcement. The company is also scheduled to report its third quarter 2026 financial results on November 5 before U.S. market open, as stated in a prior statement. These updates reflect Agenus’s ongoing activity in both clinical development and regulatory milestones.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.